

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

RIGEL PHARMACEUTICALS, INC.,

Petitioner,

v.

SERVIER PHARMACEUTICALS LLC

Patent Owner.

---

Case IPR2022-01423  
U.S. Patent No. 10,610,125

**JOINT MOTION TO TERMINATE**

The Parties in this case have reached a settlement that addresses this proceeding. The Parties therefore contacted the Board on December 18, 2022 to inform them of the settlement and request instructions regarding termination of this proceeding. In accordance with the Board's email instructions received on December 19, 2022, the Parties hereby jointly submit this motion to terminate. The Parties respectfully request that the Board terminate IPR2022-01423 with prejudice.

Pursuant to 35 U.S.C. § 317(b), 37 C.F.R. § 42.74, and the Board's e-mail, the Parties have concurrently filed the Settlement Agreements as Exhibits 1059 and 1060. The Parties state that there are no other agreements, oral or written, between the Parties made in connection with, or in contemplation of, the termination of the proceeding. The Parties have concurrently filed a joint request to treat the Settlement Agreements as confidential business information pursuant to 37 C.F.R. § 42.74(c), consistent with the provisions of the Agreements.

Date: December 27, 2022

Respectfully submitted,

By: /James L. Lovsin/

James L. Lovsin, Reg. No. 69,550  
lovsin@mbhb.com  
MCDONNELL BOEHNEN  
HULBERT & BERGHOFF LLP  
300 S. Wacker Drive  
Chicago, IL 60606  
312-913-0001

*Counsel for Petitioner  
Rigel Pharmaceuticals, Inc.*

/William M. Fink/

William M. Fink, Reg. No. 72,332  
tfink@omm.com  
O'MELVENY & MYERS LLP  
1625 I Street NW  
Washington D.C. 20006  
(202) 383-5300

*Counsel for Patent Owner  
Servier Pharmaceuticals LLC*